General Information of Disease (ID: DISUIBYS)

Disease Name Hereditary diffuse gastric adenocarcinoma
Synonyms
signet ring cell gastric carcinoma; signet cell adenocarcinoma; diffuse gastric cancer; signet ring gastric carcinoma; hereditary diffuse gastric adenocarcinoma; FDGC; familial diffuse gastric cancer; hereditary diffuse cancer of stomach; familial diffuse cancer of stomach; hereditary diffuse gastric cancer; HDGC
Definition An autosomal dominant inherited adenocarcinoma that arises from the gastric mucosa and is characterized by the presence of poorly cohesive malignant cells and absence of glandular formations.
Disease Hierarchy
DISTAPUS: Diffuse gastric adenocarcinoma
DISU3O86: Hereditary gastric cancer
DISUIBYS: Hereditary diffuse gastric adenocarcinoma
Disease Identifiers
MONDO ID
MONDO_0007648
UMLS CUI
C1708349
OMIM ID
137215
MedGen ID
310839
Orphanet ID
26106

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 125 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
IL1B TTRYK0X No Known Unknown [1]
ADRB1 TTR6W5O Limited Biomarker [2]
ADRB2 TTG8ZWP Limited Biomarker [2]
ANXA5 TT2Z83I Limited Biomarker [3]
AREG TT76B3W Limited Therapeutic [3]
BDNF TTSMLOH Limited Biomarker [3]
BMP7 TTKOBRA Limited Biomarker [3]
CASP8 TT6SZNG Limited Biomarker [4]
CAV1 TTXUBN2 Limited Biomarker [3]
CDH2 TT1WS0T Limited Biomarker [3]
CDKN2A TTFTWQ8 Limited Biomarker [3]
CTSL TT36ETB Limited Biomarker [3]
EBI3 TTJF68X Limited Biomarker [3]
F2R TTL935N Limited Biomarker [3]
FST TTDNM9W Limited Biomarker [3]
FYN TT2B9KF Limited Biomarker [3]
GREM1 TTOUZN5 Limited Biomarker [3]
IGFBP3 TTZHNQA Limited Biomarker [3]
IGFBP7 TTUQ01B Limited Biomarker [3]
IRS2 TTF95B8 Limited Biomarker [3]
KISS1 TTU2O6T Limited Biomarker [3]
KISS1R TT3KBZY Limited Biomarker [3]
MAPK1 TT4TQBX Limited Biomarker [2]
MAPK3 TT1MG9E Limited Biomarker [2]
MIA TT5HNVS Limited Biomarker [3]
NOS3 TTCM4B3 Limited Biomarker [3]
NT5E TTK0O6Y Limited Biomarker [3]
PLAU TTGY7WI Limited Biomarker [3]
PPARG TTT2SVW Limited Biomarker [5]
PRKCB TTYPXQF Limited Biomarker [2]
RBP4 TT0C8BY Limited Biomarker [3]
RGS2 TTKB7T3 Limited Biomarker [3]
RHOA TTP2U16 Limited Biomarker [6]
RORA TT1TYN7 Limited Biomarker [3]
RUNX3 TTKCVO7 Limited Biomarker [3]
SERPINE1 TTTO43N Limited Biomarker [3]
THBD TTAPV67 Limited Biomarker [3]
MAP3K6 TT64GC2 Supportive Autosomal dominant [7]
BCL2L1 TTRE6AX moderate Therapeutic [8]
CHEK2 TT9ABMF moderate Biomarker [9]
MUTYH TTNB0ZK moderate Genetic Variation [10]
SLC16A3 TTG6VD5 moderate Biomarker [11]
AFP TTCFEA1 Strong Biomarker [12]
AGTR2 TTQVOEI Strong Biomarker [13]
AHR TT037IE Strong Biomarker [14]
AKR1C3 TT5ZWB6 Strong Biomarker [15]
ALB TTFNGC9 Strong Biomarker [15]
APEX1 TTHGL48 Strong Biomarker [9]
APOA1 TT5S8DR Strong Biomarker [15]
ATM TTKBM7V Strong Biomarker [16]
AURKB TT9RTBL Strong Biomarker [17]
BAP1 TT47RXJ Strong Biomarker [18]
BIRC2 TTQ5LRD Strong Biomarker [19]
BIRC5 TTTPU1G Strong Biomarker [17]
BMP2 TTP3IGX Strong Biomarker [20]
CA1 TTHQPL7 Strong Biomarker [15]
CA2 TTANPDJ Strong Biomarker [21]
CCND1 TTFCJ7S Strong Biomarker [22]
CD44 TTWFBT7 Strong Biomarker [23]
CDK4 TT0PG8F Strong Biomarker [22]
CDKN1A TT9GUW0 Strong Biomarker [19]
CDKN1B TTLGFVW Strong Biomarker [24]
CLCN3 TT8XNZ7 Strong Biomarker [9]
CLN3 TTORF9W Strong Biomarker [9]
CTSC TT4H0V2 Strong Biomarker [9]
CYP2A6 TTAQ6ZW Strong Biomarker [25]
DPYD TTZPS91 Strong Biomarker [26]
ERBB2 TTR5TV4 Strong Biomarker [27]
FGFR2 TTGJVQM Strong Biomarker [28]
FGG TTR31L7 Strong Biomarker [15]
FHIT TTMS54D Strong Biomarker [29]
GAST TT4LRVO Strong Biomarker [30]
GSTP1 TT40K12 Strong Biomarker [9]
HBEGF TT15SL0 Strong Therapeutic [31]
HMOX1 TTI6V2A Strong Biomarker [32]
HRH4 TTXJ178 Strong Biomarker [33]
HSPA8 TTMQL3K Strong Biomarker [21]
HSPB1 TT9AZWY Strong Biomarker [15]
HSPD1 TT9HL5R Strong Biomarker [15]
HTR1A TTSQIFT Strong Therapeutic [34]
IL32 TTD4G7L Strong Biomarker [35]
ITGA5 TTHIZP9 Strong Biomarker [36]
ITGA8 TT1FW8B Strong Biomarker [36]
JUN TTS7IR5 Strong Biomarker [37]
JUP TTREN0G Strong Biomarker [38]
KMT2A TT1GNDM Strong Biomarker [39]
KRAS TTM8FR7 Strong Biomarker [40]
LGALS3 TTFPQV7 Strong Biomarker [41]
M6PR TT95ICL Strong Biomarker [9]
MAP3K6 TT64GC2 Strong Genetic Variation [7]
MAPK8 TT0K6EO Strong Biomarker [42]
MET TTNDSF4 Strong Biomarker [43]
MMP10 TTXLEG7 Strong Biomarker [44]
MMP7 TTMTWOS Strong Biomarker [45]
MSLN TT4RXME Strong Biomarker [46]
MTHFR TTQWOU1 Strong Biomarker [47]
MUC1 TTBHFYQ Strong Biomarker [16]
MYC TTNQ5ZP Strong Altered Expression [48]
NOTCH2 TT82FVD Strong Biomarker [49]
NPM1 TTHBS98 Strong Biomarker [50]
PHB TT6U071 Strong Biomarker [9]
PPIA TTL2ADK Strong Biomarker [15]
PRDX5 TTLPJWH Strong Biomarker [15]
PREP TTNGKET Strong Biomarker [9]
PRNP TTY5F9C Strong Biomarker [51]
PSCA TT9T4AV Strong Biomarker [16]
RARB TTISP28 Strong Biomarker [52]
REG4 TTVZEHU Strong Biomarker [53]
RNF43 TTD91BL Strong Biomarker [54]
RPL15 TTQRVC9 Strong Biomarker [9]
RXRB TTKLV96 Strong Biomarker [9]
SERPINA1 TTA7UJC Strong Biomarker [21]
SLC1A2 TT2F078 Strong Biomarker [23]
SREBF2 TTRQ4AP Strong Biomarker [9]
STAT3 TTHJT3X Strong Biomarker [12]
TGFA TTTLQFR Strong Therapeutic [31]
TNFRSF9 TTPW9LJ Strong Biomarker [35]
TWIST1 TTX1MY7 Strong Biomarker [55]
TYMP TTO0IB8 Strong Biomarker [26]
TYMS TTP1UKZ Strong Biomarker [56]
UMPS TTAFJUD Strong Biomarker [26]
ALOX5 TTSJ6Q4 Definitive Biomarker [57]
CDH1 TTLAWO6 Definitive Autosomal dominant [58]
DNMT1 TT6S2FE Definitive Biomarker [59]
DNMT3B TT6VZ78 Definitive Biomarker [59]
------------------------------------------------------------------------------------
⏷ Show the Full List of 125 DTT(s)
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
FADS1 DE05S8C Limited Biomarker [3]
MT2A DEFKGT7 Strong Biomarker [60]
PLPP1 DE6WXTH Strong Biomarker [9]
------------------------------------------------------------------------------------
This Disease Is Related to 142 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
IL1B OT0DWXXB No Known Unknown [1]
ALDH1A3 OT1C9NKQ Limited Biomarker [3]
BNIP3 OT4SO7J4 Limited Biomarker [3]
CDKN2D OT2TTZPZ Limited Biomarker [3]
CHFR OTRAD2TT Limited Biomarker [3]
CLDN3 OT71MN9S Limited Biomarker [3]
CST7 OTQWZUVQ Limited Biomarker [3]
EEF1A2 OT9Z23K5 Limited Biomarker [3]
EPHX3 OTU7LW2F Limited Biomarker [3]
FCGBP OT63T6XQ Limited Biomarker [3]
FILIP1 OTMZD6D4 Limited Biomarker [3]
FSD1 OT8P6PT3 Limited Biomarker [3]
ICAM2 OT3E070F Limited Biomarker [3]
ID4 OTPMJ39I Limited Biomarker [3]
IL6R OTCQL07Z Limited Biomarker [3]
MARK1 OTP7KL47 Limited Biomarker [3]
MBD3L2 OTTG4S9O Limited Biomarker [3]
MLF1 OTC5BKHU Limited Biomarker [3]
MSX1 OT5U41ZP Limited Biomarker [3]
MTSS1 OT5DTDO2 Limited Biomarker [3]
MX1 OT6X8G5T Limited Biomarker [3]
PAX6 OTOC9876 Limited Biomarker [3]
PLAGL1 OTZAO900 Limited Biomarker [3]
PLIN2 OTRXJ9UN Limited Biomarker [3]
PPIC OTY5Q42N Limited Biomarker [3]
PYCARD OT67RON3 Limited Biomarker [3]
RBP1 OTRP1MFC Limited Biomarker [3]
SCRN1 OTELM5C2 Limited Biomarker [3]
SERPINB2 OT72QLZB Limited Biomarker [3]
SNAI1 OTDPYAMC Limited Biomarker [3]
SPRR2A OT62ZU6B Limited Biomarker [3]
SPZ1 OTQH8HJ5 Limited Biomarker [3]
TBX3 OTM64N7K Limited Biomarker [3]
TFAP2C OTUDIW05 Limited Biomarker [3]
TIMP3 OTDGQAD1 Limited Biomarker [3]
TNFSF9 OTV9L89D Limited Biomarker [3]
MAP3K6 OTOE0Z1R Supportive Autosomal dominant [7]
APC OTKV0TIK moderate Genetic Variation [61]
CST1 OTE4I83Q moderate Biomarker [62]
DCBLD2 OTB71I02 moderate Biomarker [63]
DLC1 OTP8LMCR moderate Therapeutic [8]
DSG2 OTJPB2TO moderate Genetic Variation [64]
ECM1 OT1K65VW moderate Biomarker [65]
ABT1 OT9YGIDB Strong Biomarker [9]
ACAD8 OT3JI5GB Strong Biomarker [9]
ACE OTDF1964 Strong Biomarker [13]
ACTC1 OTJU04B1 Strong Biomarker [15]
ALDH7A1 OTV57BZD Strong Biomarker [9]
ALDOB OT7FR69A Strong Biomarker [15]
ARFGAP2 OTIP5ZJ7 Strong Biomarker [9]
ARID1A OTRWDV3P Strong Biomarker [54]
ARL6IP5 OTYZ6BEQ Strong Biomarker [66]
ATP6V0D2 OTMOZJO0 Strong Biomarker [35]
BID OTOSHSHU Strong Biomarker [67]
BLVRB OTHCFN2C Strong Biomarker [15]
BOP1 OTMZMQDO Strong Biomarker [9]
CCT7 OTQNM3CY Strong Biomarker [9]
CKB OTUCKOTT Strong Biomarker [21]
CNPY2 OTGY8ESX Strong Biomarker [9]
COPS7A OTLHKO3M Strong Biomarker [9]
CPSF1 OTAU1KOM Strong Biomarker [9]
CTNNA2 OTJ8G92T Strong Biomarker [54]
DDB1 OTTR2L3Z Strong Biomarker [9]
DES OTI09KBW Strong Biomarker [15]
DNAJB4 OTUD01BK Strong Altered Expression [68]
DPAGT1 OTYEJAGZ Strong Biomarker [9]
DSG1 OT11HC3A Strong Biomarker [69]
ECHS1 OTS0593S Strong Biomarker [15]
EEF1A1 OT00THXS Strong Biomarker [15]
ENO1 OTB1KWJS Strong Biomarker [21]
ERCC1 OTNPYQHI Strong Biomarker [70]
ERCC2 OT1C8HQ4 Strong Biomarker [71]
EXOSC5 OTADUQ7H Strong Biomarker [9]
FAM168A OTDXQCS5 Strong Biomarker [9]
FAT4 OT7QONNV Strong Biomarker [39]
FBP1 OTQBANEP Strong Biomarker [72]
FKBP2 OTHBZHX0 Strong Biomarker [9]
FZR1 OT0WGWZS Strong Genetic Variation [73]
GADD45A OTDRV63V Strong Biomarker [74]
GKN1 OT7ZYFQ9 Strong Biomarker [21]
GLI3 OTKDOE94 Strong Biomarker [54]
GMPR2 OTKZSZPE Strong Biomarker [21]
HIKESHI OTPKV3UZ Strong Biomarker [9]
HNRNPL OT0DJX74 Strong Biomarker [9]
HOXA2 OT6G6ZIK Strong Biomarker [36]
IDH3B OTR89YF5 Strong Biomarker [9]
ING1 OTEZBRKW Strong Biomarker [9]
KLK10 OTD573EL Strong Biomarker [75]
KMT2C OTC59BCO Strong Biomarker [39]
KRT20 OT4RB40L Strong Biomarker [21]
KRT8 OTTM4X11 Strong Biomarker [21]
LRRC3B OT9VDGPR Strong Biomarker [76]
MRPL13 OT6D8Y9G Strong Biomarker [9]
MRPS11 OTEERNWQ Strong Biomarker [9]
MRPS18B OT1K9PFX Strong Biomarker [9]
MUC6 OTPVL723 Strong Biomarker [54]
NAXD OTPO2GM2 Strong Biomarker [9]
NBAS OTW9IBRI Strong Biomarker [9]
NDUFA2 OTNSTATK Strong Biomarker [9]
NDUFS1 OTTIZDFR Strong Biomarker [9]
NDUFV1 OTEVK4WW Strong Biomarker [9]
NOP56 OTT67SRZ Strong Biomarker [9]
PA2G4 OT7IG7HT Strong Biomarker [9]
PALB2 OT6DNDBG Strong Genetic Variation [77]
PDHA1 OTGEU8IK Strong Biomarker [9]
PGAM1 OTZ5DB06 Strong Biomarker [21]
PLCE1 OTJISZOX Strong Biomarker [78]
POLR3K OTZCSF6A Strong Biomarker [9]
PPP2R1A OTYA3GB4 Strong Biomarker [9]
PRKAA1 OT7TNF0L Strong Biomarker [16]
PRKAB1 OT1OG4QZ Strong Biomarker [9]
PRPF19 OTQ1STV3 Strong Biomarker [9]
PTOV1 OT94WT5X Strong Biomarker [9]
PTPA OTRGFOI7 Strong Biomarker [9]
PTPRF OTH5KF2D Strong Biomarker [9]
PTPRG OT9N2WOF Strong Biomarker [79]
PUS1 OTS2DQ0N Strong Biomarker [9]
RAD23A OTBPAWHX Strong Biomarker [9]
RANBP10 OT0ZNZ0B Strong Biomarker [9]
RARRES1 OTETUPP5 Strong Biomarker [52]
REG1A OTMHUH1D Strong Therapeutic [80]
RPL13 OTFKNTD6 Strong Biomarker [9]
RPL18 OTJCH62J Strong Biomarker [9]
RPS15 OT0WYZYG Strong Biomarker [9]
RPS19 OTBKGP48 Strong Biomarker [9]
RPS21 OT6P58W6 Strong Biomarker [9]
RPS26 OTBYTA6A Strong Biomarker [9]
RPS6 OTT4D1LN Strong Biomarker [9]
RRP9 OT97EAV4 Strong Biomarker [9]
SELENBP1 OT3NZNTR Strong Biomarker [15]
SERBP1 OTZVSU0X Strong Biomarker [9]
SMAD4 OTWQWCKG Strong Biomarker [81]
SNRPB OT3UJ4ZU Strong Biomarker [9]
SNX5 OT6ZOWMU Strong Biomarker [9]
SUCLG1 OTDCSPXH Strong Biomarker [9]
SYMPK OTYAUDXV Strong Biomarker [9]
TAF15 OTNE038N Strong Biomarker [9]
TFF2 OTRXB19X Strong Altered Expression [82]
TMEM63A OTIUZ0C7 Strong Biomarker [9]
TPM3 OT5RU5G6 Strong Biomarker [21]
TRAP1 OTNG0L8J Strong Biomarker [9]
CDH1 OTFJMXPM Definitive Autosomal dominant [58]
------------------------------------------------------------------------------------
⏷ Show the Full List of 142 DOT(s)

References

1 Rare damaging variants in DNA repair and cell cycle pathways are associated with hippocampal and cognitive dysfunction: a combined genetic imaging study in first-episode treatment-naive patients with schizophrenia. Transl Psychiatry. 2017 Feb 14;7(2):e1028. doi: 10.1038/tp.2016.291.
2 Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci. 2007 Mar;96(1):21-9.
3 Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
4 A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.Nat Genet. 2007 May;39(5):605-13. doi: 10.1038/ng2030. Epub 2007 Apr 22.
5 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
6 Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.Nat Genet. 2014 Jun;46(6):583-7. doi: 10.1038/ng.2984. Epub 2014 May 11.
7 Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet. 2014 Oct 23;10(10):e1004669. doi: 10.1371/journal.pgen.1004669. eCollection 2014 Oct.
8 Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12492-7. doi: 10.1073/pnas.1507491112. Epub 2015 Sep 23.
9 A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.PLoS One. 2011 Feb 18;6(2):e16694. doi: 10.1371/journal.pone.0016694.
10 Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China.Int J Cancer. 2006 Dec 1;119(11):2592-6. doi: 10.1002/ijc.22206.
11 MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523.
12 Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells. PLoS One. 2013;8(1):e54774. doi: 10.1371/journal.pone.0054774. Epub 2013 Jan 30.
13 Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread.Cancer Biol Ther. 2007 Aug;6(8):1218-26. doi: 10.4161/cbt.6.8.4412. Epub 2007 Aug 10.
14 A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors.Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9990-5. doi: 10.1073/pnas.152706299. Epub 2002 Jul 9.
15 Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers.Oncol Rep. 2009 Jun;21(6):1429-37. doi: 10.3892/or_00000371.
16 Loss-of-function variants in ATM confer risk of gastric cancer.Nat Genet. 2015 Aug;47(8):906-10. doi: 10.1038/ng.3342. Epub 2015 Jun 22.
17 Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005 Aug 19;334(1):207-12. doi: 10.1016/j.bbrc.2005.05.204.
18 Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30.
19 Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene. 2004 Jan 15;23(2):503-13. doi: 10.1038/sj.onc.1207173.
20 Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas.Oncogene. 2006 Apr 27;25(18):2666-73. doi: 10.1038/sj.onc.1209297.
21 Diverse proteomic alterations in gastric adenocarcinoma.Proteomics. 2004 Oct;4(10):3276-87. doi: 10.1002/pmic.200300916.
22 Cyclin D1/cdk4, estrogen receptors and , in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric carcinogenesis: immunohistochemical study.J Toxicol Sci. 2011 Jun;36(3):373-8. doi: 10.2131/jts.36.373.
23 CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011 Apr 6;3(77):77ra30. doi: 10.1126/scitranslmed.3001423.
24 P27kip1 regulates the apoptotic response of gastric epithelial cells to Helicobacter pylori.Gut. 2004 Jun;53(6):797-804. doi: 10.1136/gut.2003.032144.
25 CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1.
26 Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.BMC Cancer. 2008 Jul 25;8:210. doi: 10.1186/1471-2407-8-210.
27 MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.J Clin Oncol. 2011 Dec 20;29(36):4803-10. doi: 10.1200/JCO.2011.35.4928. Epub 2011 Oct 31.
28 Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Pharmacogenomics J. 2012 Apr;12(2):119-27. doi: 10.1038/tpj.2010.87. Epub 2010 Dec 21.
29 Regression of upper gastric cancer in mice by FHIT gene delivery.FASEB J. 2003 Sep;17(12):1768-70. doi: 10.1096/fj.03-0241fje. Epub 2003 Jul 3.
30 Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J Pharmacol Sci. 2004 Oct;96(2):134-43. doi: 10.1254/jphs.fpj04016x. Epub 2004 Oct 9.
31 Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol. 2005 Apr;55(4):393-403. doi: 10.1007/s00280-004-0904-0. Epub 2004 Oct 5.
32 Expression and function of heme oxygenase-1 in human gastric cancer.Exp Biol Med (Maywood). 2012 Apr;237(4):362-71. doi: 10.1258/ebm.2011.011193. Epub 2012 Apr 4.
33 Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. PLoS One. 2012;7(2):e31207. doi: 10.1371/journal.pone.0031207. Epub 2012 Feb 20.
34 HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer.Histopathology. 2011 Apr;58(5):669-78. doi: 10.1111/j.1365-2559.2011.03818.x. Epub 2011 Mar 30.
35 Expression of acidosis-dependent genes in human cancer nests.Mol Clin Oncol. 2014 Nov;2(6):1160-1166. doi: 10.3892/mco.2014.344. Epub 2014 Jul 11.
36 Quantitative expression of the homeobox and integrin genes in human gastric carcinoma.Int J Mol Med. 2007 Oct;20(4):621-9.
37 Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. Cancer Sci. 2007 May;98(5):707-15. doi: 10.1111/j.1349-7006.2007.00435.x. Epub 2007 Mar 9.
38 Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer.Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2272-4. doi: 10.1158/1055-9965.EPI-12-1110. Epub 2012 Oct 15.
39 Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.Nat Genet. 2012 May;44(5):570-4. doi: 10.1038/ng.2246.
40 Point mutations of K-ras and H-ras genes in forestomach neoplasms from control B6C3F1 mice and following exposure to 1,3-butadiene, isoprene or chloroprene for up to 2-years.Chem Biol Interact. 2001 Jun 1;135-136:373-86. doi: 10.1016/s0009-2797(01)00179-x.
41 Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of -catenin in gastric cancer. Clin Exp Metastasis. 2011 Dec;28(8):743-50. doi: 10.1007/s10585-011-9406-8. Epub 2011 Jul 13.
42 c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.Cancer Res. 2008 Jul 1;68(13):5031-9. doi: 10.1158/0008-5472.CAN-07-6332.
43 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
44 Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10. J Nutr Biochem. 2012 Nov;23(11):1434-9. doi: 10.1016/j.jnutbio.2011.09.004. Epub 2012 Jan 27.
45 Association of MMP7 -181AG Promoter Polymorphism with Gastric Cancer Risk: INFLUENCE OF NICOTINE IN DIFFERENTIAL ALLELE-SPECIFIC TRANSCRIPTION VIA INCREASED PHOSPHORYLATION OF cAMP-RESPONSE ELEMENT-BINDING PROTEIN (CREB).J Biol Chem. 2015 Jun 5;290(23):14391-406. doi: 10.1074/jbc.M114.630129. Epub 2015 Apr 6.
46 Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer.Br J Cancer. 2012 Jun 26;107(1):137-42. doi: 10.1038/bjc.2012.235. Epub 2012 May 29.
47 DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.Ann Surg Oncol. 2011 Sep;18(9):2688-98. doi: 10.1245/s10434-011-1601-y. Epub 2011 Feb 24.
48 Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer.Anticancer Res. 2017 May;37(5):2401-2406. doi: 10.21873/anticanres.11579.
49 Long Noncoding RNA (lncRNA) MIR22HG Suppresses Gastric Cancer Progression through Attenuating NOTCH2 Signaling.Med Sci Monit. 2019 Jan 23;25:656-665. doi: 10.12659/MSM.912813.
50 Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Dec;360(6):683-90. doi: 10.1007/s002109900145.
51 Hypoxia induced overexpression of PrP(C) in gastric cancer cell lines.Cancer Biol Ther. 2007 May;6(5):769-74. doi: 10.4161/cbt.6.5.4001. Epub 2007 Feb 12.
52 DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation.Cancer. 2005 Oct 15;104(8):1609-19. doi: 10.1002/cncr.21392.
53 Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007 Jun 28;26(30):4383-93. doi: 10.1038/sj.onc.1210215. Epub 2007 Jan 22.
54 Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.Nat Genet. 2014 Jun;46(6):573-82. doi: 10.1038/ng.2983. Epub 2014 May 11.
55 Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells. Clin Exp Metastasis. 2009;26(8):1013-23. doi: 10.1007/s10585-009-9291-6. Epub 2009 Oct 6.
56 Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.BMC Cancer. 2008 May 27;8:148. doi: 10.1186/1471-2407-8-148.
57 Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth. Cancer Lett. 2010 Jun 28;292(2):237-45.
58 Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
59 DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.Eur J Cancer. 2011 Aug;47(12):1817-25. doi: 10.1016/j.ejca.2011.02.024. Epub 2011 Mar 31.
60 Differential induction of Mn-containing superoxide dismutase by paraquat in peripheral lymphocytes of normal subjects and gastric cancer patients. Mol Cells. 2003 Aug 31;16(1):13-8.
61 Alternative pre-mRNA splicing in digestive tract malignancy.Cancer Sci. 2011 Feb;102(2):309-16. doi: 10.1111/j.1349-7006.2010.01797.x. Epub 2010 Dec 7.
62 Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer.Clin Chim Acta. 2009 Aug;406(1-2):45-51. doi: 10.1016/j.cca.2009.05.008. Epub 2009 May 19.
63 Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion.Mol Cancer Res. 2008 Feb;6(2):222-30. doi: 10.1158/1541-7786.MCR-07-0142.
64 Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer.J Pathol. 2005 Oct;207(2):199-206. doi: 10.1002/path.1821.
65 MiR-92a antagonized the facilitation effect of extracellular matrix protein 1 in GC metastasis through targeting its 3'UTR region.Food Chem Toxicol. 2019 Nov;133:110779. doi: 10.1016/j.fct.2019.110779. Epub 2019 Aug 28.
66 Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer.Clin Cancer Res. 2012 May 15;18(10):2987-96. doi: 10.1158/1078-0432.CCR-11-2863. Epub 2012 Mar 27.
67 Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol. 2004 Apr;202(4):439-45. doi: 10.1002/path.1532.
68 DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo.Hum Mol Genet. 2014 Apr 15;23(8):2094-105. doi: 10.1093/hmg/ddt602. Epub 2013 Nov 29.
69 The human gene (DSG3) coding for the pemphigus vulgaris antigen is, like the genes coding for the other two known desmogleins, assigned to chromosome 18.Hum Genet. 1992 May;89(3):347-50. doi: 10.1007/BF00220557.
70 Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.Biomarkers. 2011 Feb;16(1):74-82. doi: 10.3109/1354750X.2010.533284. Epub 2010 Dec 6.
71 Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.World J Gastroenterol. 2006 Oct 7;12(37):6032-6. doi: 10.3748/wjg.v12.i37.6032.
72 Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One. 2011;6(10):e25564. doi: 10.1371/journal.pone.0025564. Epub 2011 Oct 19.
73 Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer.J Clin Pathol. 2008 Jan;61(1):25-30. doi: 10.1136/jcp.2006.043679. Epub 2007 May 18.
74 Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.Clin Cancer Res. 2005 Apr 15;11(8):3025-31. doi: 10.1158/1078-0432.CCR-04-1605.
75 Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer.Cancer Lett. 2007 Jun 18;251(1):78-85. doi: 10.1016/j.canlet.2006.11.006. Epub 2006 Dec 19.
76 LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer.Cancer Res. 2008 Sep 1;68(17):7147-55. doi: 10.1158/0008-5472.CAN-08-0667.
77 Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.
78 A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma.Nat Genet. 2010 Sep;42(9):764-7. doi: 10.1038/ng.649. Epub 2010 Aug 22.
79 Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol. 2007 Nov 21;13(43):5692-8. doi: 10.3748/wjg.v13.i43.5692.
80 Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.Gastroenterology. 2005 Jun;128(7):1965-83. doi: 10.1053/j.gastro.2005.03.027.
81 Genetic variations in the SMAD4 gene and gastric cancer susceptibility.World J Gastroenterol. 2010 Nov 28;16(44):5635-41. doi: 10.3748/wjg.v16.i44.5635.
82 Spasmolytic polypeptide-expressing metaplasia associated with higher expressions of miR-21, 155, and 223 can be regressed by Helicobacter pylori eradication in the gastric cancer familial relatives.Helicobacter. 2019 Jun;24(3):e12578. doi: 10.1111/hel.12578. Epub 2019 Apr 16.